Can olmesartan (angiotensin II receptor antagonist) cause hyponatremia (low sodium levels)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 13, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

Olmesartan can cause hyponatremia in some patients, particularly those with underlying kidney disease, heart failure, or those taking diuretics concurrently, and regular monitoring of electrolyte levels is recommended to minimize the risk of morbidity and mortality. This angiotensin II receptor blocker (ARB) works by blocking the effects of angiotensin II, which leads to vasodilation and decreased aldosterone production. The reduction in aldosterone can impair sodium reabsorption in the kidneys, potentially leading to hyponatremia 1.

Mechanism and Risk Factors

The mechanism of olmesartan-induced hyponatremia is related to its effect on the renin-angiotensin-aldosterone system, which can lead to decreased sodium reabsorption in the kidneys. The risk of hyponatremia is increased in elderly patients, those taking diuretics concurrently, and patients with underlying kidney disease or heart failure 1.

Clinical Implications

Patients taking olmesartan should be monitored for symptoms of hyponatremia, which include headache, confusion, nausea, muscle weakness, and in severe cases, seizures or coma. Regular blood tests to check electrolyte levels are advisable, especially when starting treatment or adjusting dosage. If hyponatremia develops, dose adjustment or medication change may be necessary, particularly in high-risk patients 2.

Management and Treatment

The management of hyponatremia in patients taking olmesartan involves treating the underlying cause and monitoring electrolyte levels. In severe cases, hypertonic saline may be necessary to correct the sodium level, but this should be done with caution to avoid overly rapid correction, which can lead to osmotic demyelination 1.

Prevention and Monitoring

To minimize the risk of hyponatremia, patients taking olmesartan should be monitored regularly for signs and symptoms of hyponatremia, and electrolyte levels should be checked periodically. Patients with underlying kidney disease or heart failure should be closely monitored, and the dose of olmesartan should be adjusted accordingly 3.

References

Research

Hyponatraemia diagnosis and treatment clinical practice guidelines.

Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2017

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.